New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novo Nordisk A/S

NVO

Healthcare Drug Manufacturers General

Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.

Revenue
+3.87%
EPS
−17.1%
Free cash flow
−14.8%
Total debt
+30.7%

Quarter to September 2026, against a year earlier

38.51 0.38 −0.98%
Market cap
$128.6B
P/E
9.8×
Fwd P/E FY26e
—
Dividend yield
4.62%
F-score
5/9
ROIC
29.6%
Net debt / EBITDA
0.7×
Payout ratio
0.5×

Ratios over time FY16 to FY25

Returns on capital

ROIC was 27.4% in FY25, the lowest of these ten years. ROE, at 61.8%, is far above it because equity is small against the capital the business uses.

ROEROIC
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
ROE82.2%81.0%76.2%70.5%70.4%72.5%68.1%89.0%80.7%61.8%
ROIC124.7%100.8%80.9%70.7%55.5%46.9%56.4%63.5%37.6%27.4%

Debt

Net debt is 0.65× a year’s EBITDA. Debt is 0.67× equity, against 0.72× in FY24.

Debt / equityNet debt / EBITDA
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Debt / equity0.0×0.0×0.0×0.1×0.2×0.4×0.3×0.3×0.7×0.7×
Net debt / EBITDA−0.4×−0.4×−0.3×−0.2×0.0×0.1×0.0×0.0×0.5×0.7×

Cash cycle, in days

Customers pay in 105 days, inventory is held 308 days and suppliers are paid in 123. Cash is tied up for 291 days between paying for goods and being paid.

Cash cycleDays to pay suppliersDays to be paid
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Cash cycle256279286292316287232182208291
Days to pay suppliers128116140116100137200261236123
Days to be paid7977888793121119118110105

Per share, from FY16

Since FY16, per share: free cash flow has fallen 1.92% a year; revenue has grown 13.8% a year; book value has grown 19.5% a year.

Free cash flowRevenueBook value
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Free cash flow1.0×0.8×0.9×1.0×0.8×1.4×1.7×1.9×1.9×0.8×
Revenue1.0×1.0×1.1×1.2×1.3×1.5×1.7×2.3×2.9×3.2×
Book value1.0×1.2×1.2×1.4×1.6×1.8×2.0×2.6×3.5×5.0×
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
16.11 23.24 18.21 23.53 25.40 33.84 39.47 37.75 26.15 14.66
Piotroski F-Score
7 6 6 4 5 4 6 8 5 5
P/S ratio
5.47 7.89 6.52 7.51 8.38 11.48 12.38 13.57 9.10 4.83
Altman Z-Score
10.61 13.47 10.57 11.11 10.51 9.99 10.40 11.38 6.74 4.32
P/FCF ratio
15.27 27.11 22.63 25.78 35.62 33.96 34.16 45.03 37.93 51.51
Altman Z″-Score (non-manufacturers)
6.62 6.61 5.65 5.38 4.56 3.36 3.38 3.19 2.53 2.81
Beneish M-Score
(3.03) (2.63) (2.51) (2.67) (2.29) (2.12) (2.86) (2.55) (2.49) (2.51)
P/Operating CF
56.61 190.83 109.53 169.31 (956.79) (570.41) 212.83 350.14 251.59 393.97
P/B ratio
13.51 17.70 14.07 15.92 16.81 22.86 26.24 29.58 18.41 7.69
EV/Sales
5.28 7.72 6.38 7.42 8.36 11.54 12.38 13.55 9.34 5.15
EV/EBITDA
11.44 16.54 13.95 15.58 17.73 25.12 26.66 28.10 18.40 10.63
EV/FCF
14.74 26.51 22.16 25.47 35.54 34.12 34.16 44.95 38.94 54.86
Current Ratio
1.26 1.28 1.09 1.06 0.94 0.86 0.89 0.82 0.74 0.80
Net Debt/EBITDA
(0.41) (0.37) (0.30) (0.19) (0.04) 0.12 (0.01) (0.05) 0.48 0.65
Debt/Equity
0.01 0.03 0.01 0.08 0.16 0.38 0.31 0.25 0.72 0.67
ROE
82.18% 81.04% 76.24% 70.52% 70.42% 72.51% 68.14% 89.04% 80.73% 61.81%
ROA
40.03% 38.56% 36.36% 32.65% 31.47% 28.59% 24.15% 30.44% 25.87% 20.71%
ROIC
124.72% 100.83% 80.88% 70.67% 55.53% 46.86% 56.35% 63.48% 37.55% 27.38%
Return on Tangible Assets
89.22% 78.99% 82.55% 72.10% 91.99% 115.24% 102.97% 137.29% 95.40% 62.02%
Average Days of Receivables
79.01 76.96 87.76 87.20 92.54 121.32 118.61 118.27 109.87 105.33
Earnings Yield
6.21% 4.30% 5.49% 4.25% 3.94% 2.96% 2.53% 2.65% 3.82% 6.82%
Free Cash Flow Yield
6.55% 3.69% 4.42% 3.88% 2.81% 2.94% 2.93% 2.22% 2.64% 1.94%
Free Cash Flow per Share
1.18 1.00 1.02 1.12 0.98 1.65 2.00 2.27 2.27 0.99
Book value per Share
1.33 1.53 1.64 1.82 2.08 2.45 2.61 3.45 4.67 6.61
Free Cash Flow
5,952.02 4,941.16 4,926.29 5,329.69 4,577.16 7,575.55 9,081.37 10,165.74 10,100.56 4,388.93
EV/EBIT
12.19 17.61 15.11 17.26 19.62 27.70 29.28 30.68 21.13 12.46
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026